Evaluation in Nonhuman Primates of Vaccines against Ebola Virus

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Geisbert, Thomas W. ; Pushko, Peter ; Anderson, Kevin ; Smith, Jonathan ; Davis, Kelly J. ; Jahrling, Peter B.
• Description:
  Ebola virus (EBOV) causes acute hemorrhagic fever that is fatal in up to 90% of cases in both humans and nonhuman primates. No vaccines or treatments are available for human use. We evaluated the effects in nonhuman primates of vaccine strategies that had protected mice or guinea pigs from lethal EBOV infection. The following immunogens were used: RNA replicon particles derived from an attenuated strain of Venezuelan equine encephalitis virus (VEEV) expressing EBOV glycoprotein and nucleoprotein; recombinant Vaccinia virus expressing EBOV glycoprotein; liposomes containing lipid A and inactivated EBOV; and a concentrated, inactivated whole-virion preparation. None of these strategies successfully protected nonhuman primates from robust challenge with EBOV. The disease observed in primates differed from that in rodents, suggesting that rodent models of EBOV may not predict the efficacy of candidate vaccines in primates and that protection of primates may require different mechanisms.
• Subjects:
  Animals Antibodies, Viral Ebolavirus Encephalitis Virus, Venezuelan Equine Genetic Vectors Glycoproteins Hemorrhagic Fever, Ebola Immunization Macaca Macaca Fascicularis Macaca Mulatta Nucleoproteins Replicon Vaccines, Attenuated Vaccines, Synthetic Viral Proteins Viral Vaccines

  More +
• Source:
  Emerg Infect Dis. 8(5):503-507.
• Document Type:
  Journal Article
• Volume:
  8
• Issue:
  5
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:dff9208a341d9284c7e13dff1f108187bbe9cd6c0687447eb1b1d6c3a926f245
• Download URL:
  https://stacks.cdc.gov/view/cdc/13815/cdc_13815_DS1.pdf
• File Type:
  [PDF - 348.48 KB ]